Ethical, Legal, and Social Implications of Fetal Gene Therapy

被引:3
作者
Brown, Julia E. H. [1 ,2 ]
Koenig, Barbara A. [1 ,2 ,3 ,4 ,5 ]
机构
[1] Univ Calif San Francisco, Program Bioeth, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Inst Hlth & Aging, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Dept Social, San Francisco, CA USA
[4] Univ Calif San Francisco, Dept Behav Sci, San Francisco, CA USA
[5] Univ Calif San Francisco, Human & Social Sci, San Francisco, CA USA
关键词
gene therapy; fetal treatment; prenatal therapy; ELSI;
D O I
10.1097/GRF.0000000000000653
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
As fetal gene therapies move from experimental animal models to human in utero phase I clinical trials, there is a need to consider the ethical, legal, and social implications. While fetal gene therapies are attracting more regulatory oversight than previous fetal interventions such as fetal surgery, old sociological questions should be applied to this new context. As health care pathways around fetal therapy are shaped by the ways in which a pregnant person and the fetus are constituted, and as risks and benefits are evaluated, we cannot afford to lose sight of long-term consequences, especially those pertaining to social inclusion.
引用
收藏
页码:933 / 940
页数:8
相关论文
共 31 条
  • [1] A Randomized Trial of Prenatal versus Postnatal Repair of Myelomeningocele
    Adzick, N. Scott
    Thom, Elizabeth A.
    Spong, Catherine Y.
    Brock, John W., III
    Burrows, Pamela K.
    Johnson, Mark P.
    Howell, Lori J.
    Farrell, Jody A.
    Dabrowiak, Mary E.
    Sutton, Leslie N.
    Gupta, Nalin
    Tulipan, Noel B.
    D'Alton, Mary E.
    Farmer, Diana L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (11) : 993 - 1004
  • [2] Making birth defects 'preventable': Pre-conceptional vitamin supplements and the politics of risk reduction
    Al-Gailani, Salim
    [J]. STUDIES IN HISTORY AND PHILOSOPHY OF SCIENCE PART C-STUDIES IN HISTORY AND PHILOSOPHY OF BIOLOGICAL AND BIOMEDICAL SCIENCES, 2014, 47 : 278 - 289
  • [3] Early treatment with laronidase improves clinical outcomes in patients with attenuated MPS I: a retrospective case series analysis of nine sibships
    Al-Sannaa, Nouriya A.
    Bay, Luisa
    Barbouth, Deborah S.
    Benhayoun, Youssef
    Goizet, Cyril
    Guelbert, Norberto
    Jones, Simon A.
    Kyosen, Sandra Obikawa
    Martins, Ana Maria
    Phornphutkul, Chanika
    Reig, Celia
    Pleat, Rebecca
    Fallet, Shari
    Holder, Iva Ivanovska
    [J]. ORPHANET JOURNAL OF RARE DISEASES, 2015, 10
  • [4] Dr. Pangloss's Clinic: Prenatal Whole Genome Sequencing and a Return to Reality
    Allyse, Megan
    Evans, James P.
    Michie, Marsha
    [J]. AMERICAN JOURNAL OF BIOETHICS, 2017, 17 (01) : 21 - 23
  • [5] In Utero Gene Therapy Consensus Statement from the IFeTIS
    Almeida-Porada, Graca
    Waddington, Simon N.
    Chan, Jerry K. Y.
    Peranteau, William H.
    MacKenzie, Tippi
    Porada, Christopher D.
    [J]. MOLECULAR THERAPY, 2019, 27 (04) : 705 - 707
  • [6] Ballantyne A, 2009, AM J BIOETHICS, V9, P48, DOI 10.1080/15265160902984996
  • [7] Diversity and inclusion in genomic research: why the uneven progress?
    Bentley A.R.
    Callier S.
    Rotimi C.N.
    [J]. Journal of Community Genetics, 2017, 8 (4) : 255 - 266
  • [8] Leveraging the learning health care model to improve equity n the age of genomic medicine
    Blizinsky, Katherine D.
    Bonham, Vence L.
    [J]. LEARNING HEALTH SYSTEMS, 2018, 2 (01):
  • [9] Casper M., 1998, MAKING UNBORN PATIEN
  • [10] Childerhose Janet Elizabeth, 2021, AJOB Empir Bioeth, V12, P179, DOI 10.1080/23294515.2021.1907475